Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra

I. Bruns (Boston, United States of America), M. Fitzgerald (Boston, United States of America), K. Pardali (Gotherburg, Sweden), G. Philip (Gotherburg, Sweden), K. David (Gotherburg, Sweden), A. Lena (Gotherburg, Sweden), J. Fanyi (Gotherburg, Sweden), L. Jason (Melbourne, Australia), C. David (Cambridge, United Kingdom)

Source: International Congress 2019 – Novel findings from asthma clinical trials
Session: Novel findings from asthma clinical trials
Session type: Oral Presentation
Number: 5336
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Bruns (Boston, United States of America), M. Fitzgerald (Boston, United States of America), K. Pardali (Gotherburg, Sweden), G. Philip (Gotherburg, Sweden), K. David (Gotherburg, Sweden), A. Lena (Gotherburg, Sweden), J. Fanyi (Gotherburg, Sweden), L. Jason (Melbourne, Australia), C. David (Cambridge, United Kingdom). Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra. 5336

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: